Welcome to our dedicated page for Eupraxia Pharmac SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eupraxia Pharmaceuticals Inc.'s SEC filings document a clinical-stage biotechnology issuer reporting current events on Form 6-K, with Form 40-F status indicated in the filings. Recent reports furnish press releases and exhibits covering the Diffusphere drug-delivery platform, EP-104GI clinical disclosures in eosinophilic esophagitis, RESOLVE trial scoring measures such as EREFS and EoEHSS, and scientific-meeting presentations.
The filings also record governance and securityholder matters, including executive medical leadership changes, annual general meeting notice materials, voting and record-date mechanics for common shares, and issuer identifiers such as CUSIP and ISIN. These disclosures frame Eupraxia's public-company record around clinical development, governance, and common-share voting matters.
Eupraxia Pharmaceuticals closed a public offering raising approximately US$63.2 million in gross proceeds. The deal included 7,607,145 common shares at US$7.00 per share and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each.
The company plans to use the funds mainly to advance its EP-104GI program for eosinophilic esophagitis through preclinical work, Phase 2 trials, Phase 3 preparations, and manufacturing, as well as expand EP-104GI into additional gastrointestinal indications and support broader pipeline, commercial, and corporate initiatives.
Eupraxia Pharmaceuticals Inc. has entered an underwriting agreement to sell 6,428,574 common shares and pre-funded warrants for up to 1,428,571 common shares, with an underwriters’ option to buy up to 1,178,571 additional shares. The firm shares are priced at $6.58 each and the pre-funded warrants at $6.57999 each, under a cross‑border offering led by Cantor Fitzgerald & Co. and conducted off an existing $200 million Form F‑10 shelf in Canada and the United States.
Eupraxia Pharmaceuticals Inc. is raising new capital through a public offering of common shares and pre-funded warrants for gross proceeds of approximately US$55 million. The company is selling 6,428,574 common shares at US$7.00 per share and pre-funded warrants to purchase up to 1,428,571 common shares at US$6.99999 each, with a nominal exercise price of C$0.00001 per warrant share.
The underwriters have a 30-day option to buy up to an additional 1,178,571 common shares on the same terms. Eupraxia plans to use the net proceeds mainly to advance its EP-104GI program for Eosinophilic Esophagitis through preclinical work, Phase 2 trials, Phase 3 preparations, and manufacturing, as well as to explore additional gastrointestinal indications, fund other pipeline candidates and business development, and support general corporate and growth-related needs.
Eupraxia Pharmaceuticals Inc. has filed a preliminary prospectus supplement for a proposed public offering of common shares, or pre-funded warrants, under its short form base shelf prospectus. The company also expects to grant underwriters a 30-day option to buy up to an additional 15% more securities.
The final size and pricing of the offering will be set based on market conditions and there is no assurance it will be completed. Eupraxia plans to use net proceeds mainly to advance its EP-104GI program for Eosinophilic Esophagitis through preclinical work, Phase 2 trials, Phase 3 preparation, and manufacturing.
Additional funds are expected to support new EP-104GI studies in other gastrointestinal indications, research on new pipeline candidates, business development, intellectual property expansion, and general corporate purposes, including salaries, working capital, facilities, and other administrative and capital needs.
Eupraxia Pharmaceuticals Inc. received an amended Schedule 13G showing that a group of related investment entities and individuals report beneficial ownership just under 10% of its common shares. Manchester Explorer, L.P. reports owning 4,597,217 shares, or 8.6% of the class, while Manchester Management entities each report 8.8%.
Individuals James E. Besser and Morgan C. Frank report beneficial ownership of 4,858,437 shares (9.1%) and 4,904,523 shares (9.2%), respectively, including both sole and shared voting and dispositive power. Most shares are held for advisory clients of Manchester Management PR, LLC, which generally do not exceed 5% ownership individually.
Eupraxia Pharmaceuticals reported encouraging new data from the Phase 1b/2a part of its RESOLVE trial testing EP-104GI in eosinophilic esophagitis.
At 12 weeks, patients on the highest dose (8mg/site, 20 sites, n=3) showed near-complete normalization of tissue health, with EoEHSS Grade improving 94% and Stage 97%. At 36 weeks, patients receiving 4mg/site (n=9) maintained the tissue gains first seen at week 12, and a clear dose-response was observed across dose levels.
Among patients with at least 60% of their esophagus treated, 58% achieved clinical remission at 12 weeks, 79% maintained remission at 24 weeks, and 67% maintained remission at 52 weeks. Across more than 200 patient-months of follow-up in 31 patients, EP-104GI was well tolerated, with no serious adverse events and no cases of oral candidiasis reported.
Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The report furnishes consolidated financial statements and management’s discussion and analysis for the three and nine months ended September 30, 2025, along with a November 4, 2025 press release.
The filing also includes interim certification forms signed by the Chief Executive Officer and Chief Financial Officer, and incorporates the attached financial statements and MD&A by reference into the company’s existing Form F-10 and Form S-8 registration statements.